



60th Ophthalmic Oncology Group (OOG) Meeting

Agenda, 2-4 July 2026

The Great Hall @ Barts North Wing
EC1A 7BE, London, UK



Headline sponsors:

aura

IMMUNOCORE

Platinum sponsors:

Delcath

 Eckert & Ziegler



Headline sponsors:

aura

Aura Biosciences

Aura Biosciences is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors, designed to preserve the function of organs afflicted with cancer. The company's proprietary platform is based on virus-like drug conjugates (VDCs) - a novel class of therapies in which virus-like particles are conjugated with anti-cancer agents to selectively target and destroy cancer cells while activating the immune system, with the potential to generate long-lasting anti-tumour immunity. Aura's lead candidate, bel-sar (AU-011), is currently in late-stage development for early choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. The global, randomised Phase 3 CoMpass trial — the first registration-enabling study in early choroidal melanoma — is evaluating bel-sar versus sham control. Bel-sar holds Orphan Drug Designation from both the FDA and EMA.

Headquartered in Boston, MA, Aura's mission is to grow as an innovative global oncology company that positively transforms the lives of patients.

Website:

www.aurabiosciences.com

Contact:

Joe Birkett, Executive Director, Medical Affairs (UK, EU, ROW), jbirkett@aurabiosciences.com

IMMUNOCORE

Immunocore

Immunocore is a commercial-stage biotechnology company that discovered, developed and commercialized the world's first approved T cell receptor (TCR) therapy.

Our mission is to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases, by pioneering and delivering transformative immunomodulating medicines.

Built on our proprietary ImmTAX platform, we have a diverse pipeline of bispecific therapies across a broad range of indications, including multiple cancers, HIV and HBV.

Platinum sponsors:



Eckert & Ziegler BEBIG

Eckert & Ziegler BEBIG is the Radiation Therapy business unit of Eckert & Ziegler Medical, one of two business segments of the Eckert & Ziegler Group. Alongside Radiopharma, Hot Cells, and Lab Devices, the Radiation Therapy unit contributes to the Group's broad expertise in isotope technology for medical applications, with a focus on the global provision of brachytherapy and radiotherapy products. Eckert & Ziegler BEBIG offers a comprehensive portfolio of brachytherapy solutions, including permanent prostate implants (seeds) in both loose and stranded form, as well as ophthalmic applicators for the treatment of eye tumors. The product range is further complemented by a variety of radiotherapy accessories, making Eckert & Ziegler BEBIG a trusted partner for cancer treatment centers worldwide.

Website:

<https://medical.ezag.com/en/about-us/about-radiation-therapy/>

Contact:

Eckert & Ziegler BEBIG GmbH

49 30 94 10 84 130

cs-bebig@ezag.com



Delcath

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.

DAY 1
Thursday 2 July: Experimental Science, Pathology, Ocular Surface and Adnexal day

08.50 08.55 OOG President's Welcome Alexandre Moulin

08.55 09.10 Welcome Gordon Hay & Hibba Quhill

Session: Experimental / Basic Science

Chair UK: Rumana Hussain

Chair non-UK: Erwin Brosens, NL

09.10 09.15 Session Chair Welcome

Rapid Fire Speakers

09.15 09.23 Denis Malaise, FR Murine models of intraocular tumors enable the evaluation of innovative anticancer treatments

09.24 09.32 Fabiana Lucia Bassil, IT Dynamic retinal vascular response assessed using adaptive optics in healthy eyes and radiation maculopathy

09.33 09.41 Agate Noer, NO Spatial Transcriptomic Profiling of Paired Primary and Metastatic Uveal Melanoma Reveals EMT Immune Dichotomy

09.42 09.50 Linda Di Gregorio, IT Zoledronic Acid Sensitizes Uveal Melanoma to Gamma/Delta T-Cell Immunotherapy and Directly Suppresses Tumor Proliferation

09.51 09.59 Elaine Binkley, USA Modelling MEK-inhibitor associated retinopathy in vitro using human induced-pluripotent stem cell-derived retinal pigment epithelial cells

10.00 10.08 Erwin Brosens, NL Biomarkers discriminating ocular sebaceous carcinoma from squamous cell carcinoma of the conjunctiva



10.09	10.17	Susanne Wolf, DE	Modelling Proton Irradiation Response and Immunotherapeutic Potential in Patient-Derived Uveal Melanoma Samples
10.18	10.26	Joshua Hattersley, UK	The extracellular matrix in uveal melanoma: transformations during primary tumour development to alterations during metastatic progression

10.28 10.40 Discussion and summary

10.40 11.00 Coffee break

Session: Pathology

Chair UK: Sarah Coupland

Chair non-UK: Rob Verdijk, NL

11.00 11.05 Session Chair Welcome

11.05 11.30 **Plenary Speaker:** Tero Kivela, FI
The TNM system then, now, and in the future: general principles and stepwise changes

11.30 11.55 **Plenary Speaker:** Sarah Coupland, UK
Understanding morphology and molecules in eye cancers

11.55 12.20 **Plenary Speaker:** Christian Ottensmier, UK
TBC

Rapid Fire Speakers

12.20 12.28 Alexandre Moulin, CH
Adenosquamous and mucoepidermoid conjunctival carcinoma: classification reappraisal and genetics

12.29 12.46 Discussion and summary

12.47 14.00 Lunch and Posters

**Session: Medical Oncology****Chair UK: Matthew Wheeler****Chair non-UK: Gustav Stalhammar, SE****14.00 14.05 Session Chair Welcome****14.05 14.30 Plenary Speaker: TBC****Rapid Fire Speakers****14.30 14.38** Linde van den Hoek, NL Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial**14.39 14.47** Ibrar Ahmed, UK Multimodal management of metastatic Uveal Melanoma: A systematic review of emerging Immunotherapeutic and liver-directed therapies**14.47 14.55 Discussion and summary****14.55 15.15 Coffee break****Session: Ocular Surface and Adnexal Oncology****Chair UK: Julie Connolly****Chair non-UK: Guy Misotten, BE****15.15 15.20 Session Chair Welcome****15.20 15.45 Plenary Speaker: Bitá Esmali, USA** Impact of regional lymph node metastasis on survival and yield of sentinel lymph node biopsy in patients with sebaceous carcinoma of eyelid



Rapid Fire Speakers

15.45	15.53	Paulina Bartoszek, BE	Clinical Outcomes of Lyophilized Amniotic Membrane Reconstruction Following Ocular Surface Tumor Excision
15.54	16.04	Rachna Meel, IN	Exploring the role of Systemic Chemotherapy in management of ocular surface squamous cell carcinoma
16.05	16.13	Guy Missotten, BE	Brachytherapy for limbal conjunctival melanoma with ruthenium and strontium.
16.14	16.22	Martina Angi, IT	Systemic treatment for locally advanced conjunctival carcinoma
16.23	16.31	Elvia Mastrogiuseppe, IT	Delayed ocular surface toxicity after topical mitomycin C: limbal stem cell deficiency in conjunctival melanocytic lesions
16.32	16.48	Niels Brouwer, NL	Orbital Exenteration for Conjunctival Melanoma – Experiences from a Dutch Referral Centre
16.48	17.10	Discussion and summary	
17.10	17.30	VALEDICTORIAN LECTURE	
		Martine Jager, NL	Eye colour: why it matters

DAY 2

Friday 3 July: Uveal Melanoma

Session: Aura Biosciences Sponsored Breakfast Symposium

08.00 09.00 Early choroidal melanoma – Shifting the paradigm

Session: Uveal Melanoma 1

Chair UK: Amit Arora

Chair non-UK: Antonia Jousen, DE

09.05 09.10 Session Chair Welcome

09.10 09.35 **Plenary Speaker:** Medical advances in ocular oncology
Mandeep Sagoo, UK

Rapid Fire Speakers

09.35 09.43 Basil Williams, USA Gene expression profile class changes on interval biopsies of choroidal melanocytic tumors

09.44 10.02 Gustav Stålhammar, SE Transpupillary Thermotherapy for Choroidal Melanoma Is Associated with Local Recurrence and Increased Mortality

10.03 10.11 Thomas Padley, UK Vitreoretinal surgery for intraocular complications following radiotherapy treatment of uveal melanoma

10.12 10.20 Aryana Shirzada, NL Shared decision making about choroidal melanoma treatment in The Netherlands: non-neutral framing of medical information

10.21 10.29 Zhihang Cheng, UK Diagnostic challenges in haemorrhagic melanoma

10.30 10.42 Discussion and summary

10.42 11.10 Coffee break



Session: Uveal Melanoma 2

Chair UK: Hibba Quhill

Chair non-UK: Martina Angi, IT

11.10 11.15 Session Chair Welcome

Rapid Fire Speakers

11.15	11.23	Khanh Vu, NL	Outcomes of Cataract Surgery in Patients with Irradiated Uveal Melanoma treated with Ruthenium-106 Brachytherapy or Proton Beam Therapy
11.24	11.32	Jan-Willem Beenakker, NL	Clipless positioning for ocular proton therapy
11.33	11.41	Nicholas Johnson, UK	Epidemiology of Ocular Melanoma in England between 2013–2022: a population-based retrospective cohort study
11.42	11.50	Antonia Jousen, DE	Decoding the Cellular Immune Ecosystem of Uveal Melanoma
11.51	11.59	Imran Malik, UK	One-Year Quality of Life Outcomes Across Uveal Melanoma Treatments
12.00	12.08	Raffaele Parrozzani, IT	Clinical classification of radiation maculopathy as a predictor of functional response to intravitreal dexamethasone implant
12.09	12.17	Maya Eiger-Moscovich, DE	Early Detection of Metastatic Uveal Melanoma by Plasma Cell Free DNA Methylation Patterns
12.18	12.26	Alexandre Matet, FR	Uveal Melanoma predisposition and the Lynch Syndrome Tumor Spectrum

12.26 12.40 Discussion and summary

12.40 13.40

Lunch and Posters

Session: Uveal Melanoma 3

Chair UK: Heinrich Heimann

Chair non-UK: Raffaele Parozzani, IT

13.40 13.45 Session Chair Welcome

13.45 14.10 **Plenary Speaker:** Dan Gombos, USA Paradigm Shifts in Ocular Oncology: A Quarter Century of Transformation

Rapid Fire Speakers

14.10 14.18 Marina Marinkovic, NL Local failure after ruthenium-106 plaque brachytherapy for uveal melanoma is correlated to institutes' annual treatment volume

14.19 14.27 Hibba Quhill, UK Gamma Knife Stereotactic Radiosurgery for Posterior Uveal Melanoma in the Modern Era: Clinical Outcomes and the Impact of Dose Reduction from 35 to 30 Gray

14.28 14.36 Nikolaos Bechrakis, DE Endoresection of large uveal melanoma after preoperative neoadjuvant radiotherapy. Functional results and complications

14.37 14.45 Asterios Diafas, UK Proton beam radiotherapy for uveal melanoma: Outcomes from the largest UK cohort

14.46 14.54 Kalinka Radlanski, DE Plaque Brachytherapy Versus Proton Beam Therapy for Juxta-Foveal Uveal Melanoma: Preliminary Results From a Swedish-German Matched Cohort Study on Long-term Survival and Visual Acuity

14.55 15.20 Discussion and summary

15.20 15.40

Coffee break

Session: Uveal Melanoma 4

Chair UK: Vikas Chadha

Chair non-UK: Iwona Rospond Kubiak, PL

15.40 15.45 Session Chair Welcome

Rapid Fire Speakers

15.45	15.53	Natalie Woods, UK	PRAME protein expression in uveal melanoma: a single-centre biobank study.
15.54	16.02	Rumana Hussain, UK	Thin and ultrathin biopsies for choroidal lesions
16.03	16.11	Jens Heufelder, DE	Ocular Proton Therapy in Europe - an Overview
16.12	16.20	Sally Owens, IE	PRAME predicting outcome in Uveal Melanoma
16.21	16.29	Danial Mohabati, NL	MR-derived tumor and retinal detachment volumes are predictive of enucleation after proton beam therapy for uveal melanoma
16.30	16.38	Ann Schalenbourg, FR	Anti-VEGFs in radiation maculopathy following proton therapy for choroidal melanoma: OCT/OCTA biomarkers predictive of visual and anatomical results
16.39	16.47	Iwona Rospond-Kubiak, PL	OOG collaborative study on extraocular extension of uveal melanoma

16.48 17.15 Discussion and summary

DAY 3

Saturday 4 July: Retinoblastoma and Other Tumours

Session: Immunocore Sponsored Breakfast Symposium

08.00 09.00 Surveillance of metastatic uveal melanoma across Europe:
How can we optimise this?

Session: Retinoblastoma 1

Chair UK: Ashwin Reddy

Chair Non-UK: Alexandre Moulin, FR

09.00 09.05 Session Chair Welcome

09.05 09.30 **Plenary Speaker:** Aqueous humor liquid biopsy in diagnosis
Jesse Berry, USA and management of retinoblastoma and
other intraocular lesions

Rapid Fire Speakers

09.30 09.38 Laurence Desjardins, FR AMCC retinoblastoma program in sub-
Saharan Africa

09.39 09.47 Amr Wassef, UK Outcomes and Complications of Intra-
Arterial Chemotherapy technique for
Retinoblastoma: A 6-Year Experience from a
UK Tertiary Center

09.48 09.56 Mona Mohammad, JO Intra-Arterial Melphalan Chemotherapy for
Retinoblastoma in a Developing Nation:
Real-World Outcomes and Prognostic
Factors

09.57 10.05 Nakul Verma, IN Cavitory Retinoblastoma: Clinical features
and Treatment Outcomes

10.06 10.14 Antriksh Wahi, IN High-Dose Chemotherapy with Autologous
Stem Cell Transplantation in Recurrent
Advanced Intraocular Retinoblastoma with
Anterior Segment Involvement: A Novel
Application

10.15 10.25 Discussion and summary

10.25 10.50 Coffee break

Session: Retinoblastoma 2

Chair UK: Manoj Perelukar

Chair non-UK: Laurence Desjardin, FR

10.50 10.55 Session Chair Welcome

10.55 11.20 **Plenary Speaker:** Global Retinoblastoma
Didi Fabian, IL

Rapid Fire Speakers

11.20 11.28 Eva Biewald, DE High-dose intravitreal Topotecan (90µg) as monotherapy in the treatment of perifoveal recurrent or primary retinoblastomas

11.29 11.37 Andrew Stacey, USA The Prognostic Importance of the Allele-of-Origin in RB1 Mutations

11.38 11.46 Arun Singh, USA Suprachoroidal Delivery of Topotecan for Retinoblastoma: A Preclinical Study

11.47 11.55 M. Ashwin Reddy, UK Does enucleation in infants with retinoblastoma cause nystagmus?

11.56 12.15 Discussion and summary

Session: Uveal Melanoma Hang Over

Chair UK: Gordon Hay

Chair non-UK: Vicktoria Vishnevskia-Dai, IL

12.15 12.20 Session Chair Welcome

Rapid Fire Speakers

12.20 12.26 Gulmeena Hussain, IN Outcomes Following Treatment with Notched Proton Beams for Peripapillary Choroidal Melanomas

12.27	12.33	Augustina Grigaite, CH	Medium to long-term results of Baerveldt shunt surgery for glaucoma secondary to anterior uveal melanoma treated with proton therapy
12.34	12.40	Natasha van Poppelen, NL	Chromosome 8q in Uveal Melanoma prognosis: interdependent prognostic factor or related to genomic parameters?
12.41	12.47	Heinrich Heimann, UK	Retinal recurrences following surgical endoresection and adjuvant Ruthenium106-plaque brachytherapy for large choroidal melanoma
12.48	12.54	Guy Negretti, UK	The characteristics of uveal melanoma in Australia and the UK
12.55	13.01	Beatrice Gallo, UK	Validation of MOLES score for small choroidal melanoma: impact of assuming enlargement in sizable lesions

13.02 13.20 Discussion and summary

13.20 14.20 Lunch and Posters

14.20 15.00 OOG Business Meeting Chair: Alexandre Moulin, CH

Session: Other Tumours Chair UK: Noel Horgan, IE Chair non-UK: Marina Marikovic, NL

15.00 15.05 Session Chair Welcome

Rapid Fire Speakers

15.05	15.13	Pranvera Emini, DE	Optical Coherence Tomography for the Differentiation of Retinal Astrocytomas from Retinoblastomas and Retinomas
15.14	15.22	Julien Schaller, DE	Iris Metastasis: A Single Centre Case Series of 40 Patients



15.23	15.31	Jørgen Krohn, NO	Bilateral ciliary body medulloepithelioma in an adult: a case and literature review
-------	-------	------------------	---

15.32	15.44	Discussion and summary	
--------------	--------------	-------------------------------	--

15.45	16.10	Coffee break	
--------------	--------------	---------------------	--

16.10	17.10	OOG Collaborative initiatives Meeting	Chair: Ulrich Pfeffer, IT
-------	-------	---------------------------------------	---------------------------

17.10	17.30	Finale Lecture	
		Bertil Damato, UK	A fulfilling career in ocular oncology

17.30	17.35	OOG President's Closing Remarks	Alexandre Moulin
-------	-------	---------------------------------	------------------

17.35	17.40	Meeting Close	Gordon Hay
-------	-------	---------------	------------

Posters

Thursday 2 July: Experimental Science, Pathology, Ocular Surface and Adnexal day

Title	Presenting Author
Spatiotemporal Analysis of Melanocyte Migration and Differentiation in Human Embryonic Ocular Development Using Multiplex Immunofluorescence	James Draper, UK
Spatial phenotyping of CD68+ macrophage populations in uveal melanoma using a graphneural network approach	Max Jackson, UK
Proteomic Insights Into the Bidirectional Interaction Between Uveal Melanoma and Hepatic Stellate Cells	Karen Aughton, UK
Cannabinoid receptor 2 inverse agonisms as a novel therapeutic strategy against metastatic uveal melanoma	Camilla Maria Fontana, IE
When floaters signal metastases: Vitreous seeding from cutaneous melanoma responding to immune checkpoint inhibitors	Bayan Shahin, UK
Orbital Exenteration for Conjunctival Melanoma – Experiences from a Dutch Referral Centre	Niels Brouwer, NL
Bilateral ocular surface squamous neoplasia (OSSN): a case series	Grace George, UK
The orbit at the crossroads: rare orbital involvement as a hallmark of systemic and surface malignancies	Anna Giulia Di Dario, IT
When Benign Mimics Malignancy: A Rare Presentation of a Pigmented Orbital Lesion	Rana Khalil, UK
Bridging the Gap: Quality of Life One Year after Conjunctival Melanoma Treatment	Catherine Kwok, UK

Posters

Friday 3 July: Uveal Melanoma

Title	Presenting Author
Retrospective Registry for Uveal Melanoma in Lebanon: 10-year Single-Center Experience of a Major Referral Center in the Middle East and North Africa Region	Amal El Masri, LB
Factors prognostic of severe visual impairment after proton beam therapy for uveal melanoma	Lennart Pors, NL
Three years of ocular proton therapy in The Netherlands, clinical results	Coen Rasch, NL
Tumour control, eye retention and visual acuity after plaque radiotherapy for ciliary body-involving uveal melanoma.	Denis Nevrov, IE
Circulating Tumor DNA for Surveillance and Treatment Monitoring in Uveal Melanoma	Henrik Jespersen, NO
Uveal Melanoma: Metastatic Risk Stratification and Onset of Metastases — A Comparative Analysis	Monica Maria Pagliara, IT
Mapping HLA-A*02:01 prevalence in a Scottish ocular melanoma cohort	Cameron Greenhalgh, UK
Clinical Outcomes of Choroidal Melanomas associated with ocular Inflammation	Maria Grazia Sammarco, IT
Long-Term Outcomes of Surgical Resection and Episcleral Brachytherapy for Anterior Uveal Tumours: Extended Single-Centre Experience.	Maria Isabel Relimpio Lopez, ES
Paediatric uveal melanoma in Ireland 2010-2026; A rising trend?	Noel Horgan, IE
Uveal Melanoma in Oculodermal Melanocytosis (Nevus of Ota): A Five-Patient Case Series Emphasizing the Importance of Regular Screening	Vicktoria (Vicky) Vishnevskia-Dai, IL
Natural history of uveal melanoma in an institutional series (2009-2026)	Sapna Patel, US
Genetic Signatures of Extraocular Extension in Uveal Melanoma	Hans Witzenhausen, SE
A wrong-way-round heterochromic uveitis	Mari Mansikkamäki, FI

Posters

Saturday 4 July: Retinoblastoma and Other Tumours

Title	Presenting Author
Iris cavernous hemangioma – a case report	Yasmin Haim, IL
Optic Disc Melanocytoma in a Low-Resource Environment: Diagnostic Constraints and Clinical Monitoring.	Chigozie Echieh, NG
Cancer-Associated Retinopathy Versus BDUMP: A Diagnostic and Therapeutic Dilemma in Ocular Oncology	Maria Pefkianaki, GR
Vitreous metastasis from acral lentiginous melanoma in a patient undergoing checkpoint inhibitor therapy	Pranati Ahuja, US
Iris and ciliary body lymphoma	Alenka Lavric Groznic, SI
Rare presentation of Nevus of Ota	Ekaterina Semenova, US
Surgical outcomes of Cutler-Beard advancement flap – case series	Emilia Zwolińska, PL
Periocular sebaceous carcinomas: clinical presentation, pathological features, and therapeutic outcomes in a tertiary ocular oncology center	Laura Ninet, FR



Social programme

Thursday 2nd July

Wine reception and canapes, 6-8pm

The Great Hall @ Barts North Wing
EC1A 7BE

Friday 3rd July

Buffet reception, 6.45-10.30pm

House of Commons
SW1A 0AA

(30 minutes by public transport)

Ticketed – you will not be able to enter without your ticket/s

Saturday 4th July

4th July Party, 6.30-9.30pm

Charterhouse Square Lawn
Queen Mary University of London
EC1M 6BQ
(7 minute walk)